PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 11, 2014Journal of Clinical Oncology666 citations

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

MTMax S. ToppNGNicola GökbugetGZGerhard Zugmaier

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Topp et al. (2014) studied this question.

synapsesocial.com/papers/6a0375f3fb1d234f482e6e7ahttps://doi.org/10.1200/jco.2014.56.3247
View Full Paper
Ask AI
Bookmark
Share